Effect of coffee consumption on patients with liver fat
Not Applicable
Recruiting
- Conditions
- on-Alcoholic Fatty Liver DiseaseC06.552.241.519
- Registration Number
- RBR-5ysgfv
- Lead Sponsor
- Instituto de Nutrição Josué de castro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients diagnosed with non-alcoholic fatty liver disease through Fibroscam; both genders; aged between 18 and 65 years.
Exclusion Criteria
Patients with: another cause of hepatic steatosis (alcohol, virus, genetics) or advanced liver disease; chronic kidney disease
thyroid diseases; cushing's syndrome; cancer; pregnant or lactating women; history of upper gastrointestinal surgery; use of medications for weight loss; report of sensitivity to coffee; consumption of more than 3 cups of coffee per day.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Coffee consumption mechanism oxidative stress gut microbiota NAFLD PNPLA3 polymorphism liver steatosis
Comparative effectiveness coffee versus lifestyle modification pharmacotherapy NAFLD steatosis reduction outcomes
PNPLA3 genotype biomarker predicting NAFLD response coffee dietary intervention liver fat
Safety profile high coffee intake NAFLD patients metabolic cardiovascular adverse effects
Dietary interventions targeting gut microbiota oxidative stress NAFLD treatment compared coffee